FIRM FIXED PRICE
JAZZ PHARMACEUTICALS, INC - XYWAV 500MG/ML ORAL SOLUTION (SOLN).
PIID: 36C26025F0025
Signed Date: Jan 15, 2026Effective Date: Oct 1, 2024End Date: Closed on Sep 30, 2025
Key Details
Description
XYWAV 500MG/ML ORAL SOLUTION (SOLN).
Contractor Information
Similar Awards
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 NOVEMBER
MCKESSON CORPORATION
$1.4B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 OCTOBER
MCKESSON CORPORATION
$1.2B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 DECEMBER
MCKESSON CORPORATION
$1.1B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 JANUARY
MCKESSON CORPORATION
$1.1B
LENALIDOMIDE FOR THE SALISBURY VAMC, CHARLOTTE HCC, AND KERNERSVILLE HCC.
EXELAN PHARMACEUTICALS INC
$5.1M
Stay Updated
Get notified about new opportunities matching your interests.
Related
Agencies
Vendors